A Double-blind, Randomized, Multi-center, Placebo-controlled, Parallel-group Study to Assess the Effect of Creon on Pancreatic Exocrine Insufficiency in Subjects with Diabetes Mellitus type 2

Trial Profile

A Double-blind, Randomized, Multi-center, Placebo-controlled, Parallel-group Study to Assess the Effect of Creon on Pancreatic Exocrine Insufficiency in Subjects with Diabetes Mellitus type 2

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 30 Jul 2014

At a glance

  • Drugs Pancrelipase (Primary)
  • Indications Exocrine pancreatic insufficiency
  • Focus Therapeutic Use
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 19 Jun 2014 Status changed from recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
    • 17 Dec 2013 New source identified and integrated: ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top